M
M. Tiseo
Researcher at Yale Cancer Center
Publications - 25
Citations - 785
M. Tiseo is an academic researcher from Yale Cancer Center. The author has contributed to research in topics: Crizotinib & ALK inhibitor. The author has an hindex of 5, co-authored 25 publications receiving 530 citations.
Papers
More filters
Journal ArticleDOI
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
D. Ross Camidge,Hye Ryun Kim,Myung-Ju Ahn,James Chih-Hsin Yang,Ji Youn Han,Jong Seok Lee,Maximilian Hochmair,Jacky Yu-Chung Li,Gee Chen Chang,Ki Hyeong Lee,Cesare Gridelli,Angelo Delmonte,Rosario Garcia Campelo,Dong Wan Kim,Alessandra Bearz,Frank Griesinger,Alessandro Morabito,Enriqueta Felip,Raffaele Califano,Sharmistha Ghosh,Alexander I. Spira,Scott N. Gettinger,M. Tiseo,Neeraj Gupta,Jeff Haney,David Kerstein,Sanjay Popat +26 more
TL;DR: Among patients with ALK‐positive NSCLC who had not previously received an ALK inhibitor, progression‐free survival was significantly longer among patients who received brigatinib than among those who received crizotinib.
Journal ArticleDOI
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
S.S. Ramalingam,Jhanelle E. Gray,Yuichiro Ohe,Byoung Chul Cho,Johan Vansteenkiste,C. Zhou,Thanyanan Reungwetwattana,Ying Cheng,Busyamas Chewaskulyong,Riyaz Shah,K.H. Lee,Parneet Cheema,M. Tiseo,Thomas John,Meng-Chih Lin,Fumio Imamura,Rachel Hodge,Yuri Rukazenkov,Jean-Charles Soria,David Planchard +19 more
TL;DR: Osimertinib significantly improved OS vs comparator EGFR-TKI in the phase III FLAURA study, and the safety profile appears consistent with previously reported data.
Journal ArticleDOI
Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial
R. Camidge,H.R. Kim,Myung-Ju Ahn,J.C.-H. Yang,J-Y. Han,Maximilian Hochmair,K.H. Lee,Angelo Delmonte,M.R. Garcia Campelo,Dai Woo Kim,Frank Griesinger,Enriqueta Felip,Raffaele Califano,Alexander I. Spira,Scott N. Gettinger,M. Tiseo,Q. Ni,Pingkuan Zhang,Sanjay Popat +18 more
Journal ArticleDOI
OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
M-J. Ahn,D.R. Camidge,M. Tiseo,Karen L. Reckamp,Karin Holmskov Hansen,S-W. Kim,Rudolf M. Huber,Howard West,H. Groen,Maximilian Hochmair,Natasha B. Leighl,Scott N. Gettinger,Corey J. Langer,Luis Paz-Ares,Egbert F. Smit,Edward S. Kim,W. Reichmann,David Kerstein,D. Kim +18 more
Journal ArticleDOI
Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)
J. Baena Espinar,Valter Torri,Jennifer G. Whisenant,Fred R. Hirsch,J. Rogado,J. De Castro Carpeno,Balazs Halmos,Giovanni Luca Ceresoli,A. G. Rueda,M. Tiseo,Enriqueta Felip,M. Majem Tarruella,Isabelle Monnet,U. Tapan,Heather A. Wakelee,Li-Ching Huang,M.C. Garassino,Solange Peters,Leora Horn,Matthew D. Hellmann +19 more
TL;DR: Facing this ongoing global pandemic, TERAVOLT is the largest thoracic malignancy database confirming the high risk for COVID-19 mortality in this specific patient group and patients on immunotherapy appeared to be at decreased risk for mortality.